Search the Newsreel

The Bull Case For Celcuity (CELC) Could Change Following Revtopik’s FDA Approval And NCCN Category 1 Status

Celcuity Inc. (CELC) reported a wider Q2 net loss of US$78.86 million but secured FDA approval and NCCN Category 1 status for Revtopik, its breast cancer drug. This development significantly alters the company's investment narrative, shifting focus from gedatolisib's potential to Revtopik's commercialization and …

Celcuity (NASDAQ:CELC) Stock Rating Lowered by Wall Street Zen

Wall Street Zen downgraded Celcuity (NASDAQ:CELC) from a "sell" to a "strong sell," despite a "Moderate Buy" consensus from other analysts with an average price target of $153.64. The company's shares opened at $92, below its 52-week high, and reported a larger-than-expected quarterly loss …

Melco Resorts And Entertainment (MLCO) Stock Shrugs Off Margin Pressure##

Liquidity Mapping Around (DCTH) Price Events

This article provides a liquidity mapping analysis for Delcath Systems Inc. (DCTH), indicating strong sentiment across all horizons and compelling upside potential. It details AI-generated institutional trading strategies for various risk profiles, including position, momentum breakout, and risk hedging strategies, along with multi-timeframe signal …

Celcuity (NASDAQ:CELC) Releases Quarterly Earnings Results, Misses Estimates By $0.28 EPS

Celcuity (NASDAQ:CELC) recently reported its quarterly earnings, missing analyst estimates with a loss of $1.44 per share against a consensus of $1.16, and revenue of $0.09 million, significantly below the $4.42 million forecast. Despite the financial miss, the company highlighted the FDA approval of …

FuelCell Energy Inc. stock rises Friday, outperforms market

FuelCell Energy Inc. (FCEL) stock rose significantly on Friday, gaining 9.98% to $22.37, despite a generally negative day for the broader market. Both the NASDAQ Composite Index and the Dow Jones Industrial Average experienced declines. The company's stock closed 40.95% below its 52-week high …

Legal & General Group (FCEL) reports 2.42M FuelCell Energy shares in 13G/A

Legal & General Group Plc and its investment management affiliates reported beneficial ownership of 2,419,645 shares of FuelCell Energy, Inc. common stock, representing 3.6% of the class. This disclosure was made in a SCHEDULE 13G/A filing, indicating shared voting and dispositive power among the …

Celcuity (NASDAQ:CELC) Shares Gap Down on Disappointing Earnings

Celcuity remains a Buy as FDA approval and strong trial data boost confidence in its cancer drug launch.

Celcuity Inc. has received a "Buy" rating following the FDA approval of its cancer drug REVTORPYK/gedatolisib and its quick inclusion in NCCN Category 1 guidelines, which is expected to aid adoption. Despite high upfront commercial investments and a significant valuation, the company's strong cash …

Delcath Systems updates bylaws to designate Delaware courts as exclusive forum

Delcath Systems (NASDAQ:DCTH) has amended its bylaws to designate Delaware courts as the exclusive forum for internal corporate claims and federal district courts for claims under the Securities Act of 1933. This decision, effective immediately, follows a recommendation from the Nominating and Corporate Governance …

Stifel cuts Celcuity stock price target on refined market model

Stifel lowered its price target for Celcuity Inc. (NASDAQ:CELC) to $150 from $175, while maintaining a Buy rating, citing refined market model inputs for Revtorpyk and higher future administrative expenses. Despite the stock's strong performance, InvestingPro analysis suggests it might be overvalued, and analysts …

Celcuity Inc. Stock 12‑Month Price Target Cut to $160.64, Implies 85% Upside

Analysts have adjusted Celcuity Inc.'s average 12-month price target from $163.55 to $160.64, with individual forecasts ranging from $140 to $178 per share. This new target suggests an 85% potential upside from the Aug. 13 closing price. The consensus rating for Celcuity Inc. remains …

Form 8K Delcath Systems Inc For: 14 August By Investing.com

This article announces the filing of a Form 8K by Delcath Systems Inc. on August 14th. It is a brief news item from Investing.com, providing basic information about the regulatory filing.

Needham cuts Celcuity stock price target on updated revenue model

Needham has reduced its price target for Celcuity Inc (NASDAQ:CELC) shares to $140 from $157, while maintaining a Buy rating. This adjustment follows the approval and upcoming launch of Revtorpyk, with Needham updating its revenue models to an incidence-based approach and incorporating new pricing …

Delcath Systems (DCTH) adopts new exclusive forum clauses in amended bylaws

Delcath Systems, Inc. (DCTH) has amended its bylaws, effective August 12, 2026, to include exclusive forum provisions for legal disputes. The updated bylaws designate the Court of Chancery of the State of Delaware as the exclusive forum for internal corporate claims, and the federal …

Earnings Flash (MRD.TO) Melcor Developments Ltd. Reports Q2 Revenue C$62.0M

Melco Resorts (Nasdaq: MLCO) Q2 2026 earnings: EBITDA falls as buybacks and refinancing grow

Melco Resorts & Entertainment Limited reported a decrease in Q2 2026 operating revenues to US$1.25 billion, down from US$1.33 billion year-over-year, primarily due to weaker Macau gaming performance. Despite this, net income attributable to the company rose to US$22.7 million, or US$0.06 per ADS, …

Melco Resorts & Entertainment (MLCO) Following Q2 Pressure Has Undervaluation Back In Focus

Melco Resorts & Entertainment (MLCO) is gaining attention after its Q2 2026 results showed operational pressure in Macau but highlighted future capital returns and global diversification. The stock, currently trading at US$5.50, is considered 31% undervalued with a narrative fair value of $7.97, suggesting …

Celcomdigi Berhad Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026

Dimensional Fund Advisors LP Purchases 256,640 Shares of FuelCell Energy, Inc. $FCEL

Dimensional Fund Advisors LP significantly increased its stake in FuelCell Energy, Inc. (NASDAQ:FCEL) by 459.1% in the first quarter, acquiring an additional 256,640 shares and bringing its total holdings to 312,536 shares valued at approximately $2.04 million. Despite institutional interest, FuelCell Energy reported disappointing …

Celcuity Inc. Reports Release of Second Quarter 2026 Financial Results and Provides Corporate Update

Celcuity Inc. announced its Q2 2026 financial results, highlighted by the FDA approval of REVTORPYK (gedatolisib) for HR+/HER2- PIK3CA Wild-Type breast cancer and its inclusion in NCCN guidelines. The company plans a commercial launch for REVTORPYK in late Q3 2026 and intends to submit …

Melcor Developments Q2 Profit Rises

(RTTNews) - Melcor Developments (MRD.TO) released earnings for its second quarter that Increased, from the same period last year The company's bottom line came in at C$21.94 million, or C$0.73 per share. This compares with C$7.26 million, or C$0.24 per share, last year. The …

Celcuity (CELC) Wins FDA Approval As Investors Weigh Whether The Pullback Is A Buying Opportunity

Celcuity (CELC) has received FDA approval for REVTORPYK for certain metastatic breast cancer patients and its inclusion in NCCN guidelines. Despite this positive news, the stock has experienced a significant pullback, falling 22% over 30 days and 37.1% over 90 days. Analysts currently value …

Celcuity Q2 Earnings Call Highlights

Key Points Interested in Celcuity, Inc.? Here are five stocks we like better. REVTORPYK launch remains on track: Celcuity expects commercial shipments of its FDA-approved gedatolisib therapy for certain advanced breast cancer patients to begin in late Q3 2026. The treatment has a $30,000 …

CELCUITY ($CELC) Releases Q2 2026 Earnings

CELC: FDA approval, strong trial data, and robust cash position set stage for late Q3 launch

Celcuity Inc. (CELC) received FDA approval for REVTORPYK for HR-positive, HER2-negative advanced breast cancer, supported by strong trial data and NCCN guideline inclusion. Despite a Q2 net loss of $78.9M, the company has a robust cash position due to a $575M convertible note, setting …

Earnings call transcript: Celcuity Q2 2026 loss widens as launch nears

Melcor Developments announces second quarter results, declares quarterly dividend of $0.15 per share

Celcuity Inc. (NASDAQ: CELC) deepens loss as it raises $575M in converts

Celcuity beats second quarter loss estimates

Celcuity Inc. reported an adjusted loss of $1.07 per share for the second quarter of 2026, surpassing analyst estimates. The company's shares rose 1% after the announcement, driven by the recent FDA approval of its breast cancer treatment, REVTORPYK. Celcuity expects to begin shipments …

Celcuity GAAP EPS of -$1.44 misses by $0.28

* Celcuity press release [https://seekingalpha.com/pr/20619145-celcuity-inc-reports-release-of-second-quarter-2026-financial-results-and-provides-corporate] (CELC [https://seekingalpha.com/symbol/CELC]): Q2 GAAP EPS of -$1.44 misses by $0.28. * Total operating expenses were $66.1 million for the second quarter of 2026, compared to $44.0 million for the prior year period. Research and development (“R&D”) expenses were $31.1 …

Earnings Flash (CELC) Celcuity Inc. Posts Q2 Adjusted Loss $1.07 per Share, vs. FactSet Est of $-1.12

Celcuity Inc. (CELC) reported a Q2 adjusted loss of $1.07 per share, which was better than the FactSet estimate of $-1.12 per share. The article, published on August 13, 2026, also noted that Celcuity's Q2 adjusted loss widened. This news follows several recent developments …

FuelCell Energy (NASDAQ:FCEL) Shares Down 7.1% - Here's What Happened

FuelCell Energy (NASDAQ:FCEL) shares dropped 7.1% on Thursday, closing at $20.13, with trading volume below average. The company reported a significant quarterly loss and lower-than-expected revenue. Analyst sentiment is mixed, resulting in a consensus "Hold" rating and an average price target of $22.83.